Cmed opens subsidiary in France

Written by Cmed

Cmed has now established a wholly owned subsidiary, Cmed France.

According to Cmed Group CEO David Connelly, “This is a perfect time for us to extend our European presence. Cmed France will enable us to further enhance our support of French customers as well as support the conduct of clinical trials in France and mainland Europe. Our customers wanted us to have a greater French presence, so we responded.”

He added “Cmed France will also enable us to accelerate organic growth of our CRO operations and provision of our encapsia data system. The latter is particularly relevant and beneficial right now as it is able to provide huge flexibility to overcome clinical trial data collection problems caused by the impact of COVID-19”.

For over 20 years, Cmed has combined deep data knowledge with technology and clinical operations expertise and the company is known for providing flexible solutions for complex and challenging studies.

COO Stephanie Langouet commented, “Our local presence in France has been continuously expanding so it was time for us to establish an affiliate business. Our European footprint is key for Cmed to keep delivering complex, demanding and innovative clinical trials in various therapeutic areas. Our French affiliate also allows us to be even closer to Key Opinion Leaders and Oncology Networks.”

Cmed SAS
58, Avenue de Wagram
75017 Paris
+33 (0) 1 85 14 99 01